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Transplantationcer still elude detection. Complete autopsy of donors is even less frequently performed, due to economic issues
and increasing availability of high-quality imaging. The aim of this study is to gather evidence from the literature
on donormalignancy discovered at autopsy following organ donation and to discuss the utility and limitations ofBackground: clinical and imaging investigations allowa detailed assessment of an organ donor, but a quota of can-
autopsy practice in the field of transplantation.
Methods: A systematic search according to PRISMA guidelines was carried out in Pubmed and Embase databases
until September 2020 to select articles with reporting of cancer discovered in a donor at postmortem examina-
tion. Cancer discover in not-transplant setting were excluded. A descriptive synthesis was provided.
Results: Of 7388 articles after duplicates removal, 56 were included. Fifty-one studies reported on complete au-
topsy, while 5 dealt only with limited autopsy (prostate and central nervous system). The number of autopsies
ranged between 1 and 246 with a total of 823 autopsies performed. The most frequent cancer discovered at au-
topsy was lymphoma (n = 13, 15%), followed by renal cell carcinoma (RCC) (n= 11, 13%), non-small cell lung
cancer (NSCLC) (n= 10, 11%), melanoma (n= 10, 11%), choriocarcinoma (n= 6, 7%) and glioblastoma (GBM)
(n = 6, 7%).
Conclusions: Lymphomaandmelanoma are still difficult-to-detect cancers both during donor investigation and at
procurement, whilst prostate cancer and choriocarcinoma are almost always easily detected nowadays thank to
blood markers and clinical examination. There have been improvements with time in pre-donation detection
procedures which are now working well, particularly when complete imaging investigations are performed,
given that detection rate of CT/MRI is high and accurate. Autopsy can play a role to help to establish the correct
donor management pathways in case of cancer discover. Furthermore, it helps to better understand which can-
cers are still eluding detection and consequently to refine guidelines' assessment procedures.
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Transplantation of an organ from a donor carries an unavoidable risk
of transmission of malignancy and the risk is increasing with the in-
creasing age of potential donors. Different types of malignant lesions
have differing risks of transmission which have led to the development
of international guidelines and recommendations to guide the evalua-
tion of a donor with malignancy and to define the risk of transmission
for the recipient [1–5]. Donors with a known history of malignancy, ei-
ther recent or past, trigger increased suspicion and assessment path-
ways. In addition to donors with a history of malignancy, malignant
lesions are discovered during donor’ evaluation, both before and during
the procurement phase and after transplantation, when an autopsy is
performed on the donor. The frequency of performing an autopsy has
decreased significantly both in general and for donor assessment [6,7].
The reason for the declining autopsy rate is multifactorial, and varies
around the world: the cost of performing an autopsy [7,8]; medical
staff failing to think about/discuss an autopsy with family; reluctance
of the donor's family; together with the greater availability of imaging
techniques, which are now also replacing traditional autopsies [9]. De-
spite the increasing reliance on radiology/clinical diagnosis, this com-
bined process is imperfect, with the combined diagnosis/cause of
death being wrong compare to autopsy findings in 10–27% [7,10–12].
Autopsy confirmed and typed a suspected malignancy in 1.2% [13]. An
unsuspected malignancy was found in 8–18% [10,13], worrying in the
setting of organ donors, particularly with the increasing age of donors.
The aim of this study is to gather all the published evidence on donor
malignancy discovered at autopsy following organ donation and to dis-
cuss the utility and limitations of autopsy practice in the field of trans-
plantation. A reassessment of these cases in the current era, taking
into account ethical and economic issues, may help to further refine
the optimum donor assessment pathways.2. Materials and methods
We conducted a systematic review according to standard methods
and reporting in accordance with the appropriate guidelines, Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
[14] and Meta-Analysis of Observational Studies in Epidemiology
(MOOSE) [15].2.1. Search strategy and article screening
A systematic search was carried out without any language restric-
tions in the electronic databases Pubmed and Embase until March
2020 to identify any study documenting the discovery of a malignancy
in a donor or in a potential donor. The key terms “autopsy”, “port-
mortem”, “donor”, “organ” and “transplantation” were adequately2
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strategies are found in Supplementary Material - Appendix S1.
Two investigators (IG, SM) independently screened titles and ab-
stracts for eligibility with the aid of Rayyan QCRI reference manager
web application [16]. Disagreement was resolved by consultation of
the senior researcher (AE). Full-texts assessed for eligibility underwent
also reference hand-searching to identify relevant articles potentially
missed by the search. Inclusion criteria were the presence of at least
one donor or potential donor of organs or tissueswhere cancer was dis-
covered by means of an autopsy after transplant or after procurement,
irrespective of whether organs or tissues were transplanted or of out-
come of the recipients. When limited information was present, or it
was stated only that cancerwas discovered after transplantation,we as-
sumed that it could have been discovered with autopsy of the donor. A
limited autopsy of the central nervous system or prostate only were
considered separately from reporting of complete whole autopsy
cases. When autopsy was performed but excluded a cancer or con-
firmed a cancer suspected during donor evaluation the paper was
excluded.
Full-texts of the articles fulfilling the initial screening criteria were
acquired and reviewed for subsequent inclusion, against the eligibility
criteria, with the consultation of the third reviewer in case of
disagreement.2.2. Data extraction
Two authors (IG, SM) independently extracted data from the in-
cluded studies following a standardized extraction form. Data extracted
were: type of publication (full paper, abstract or conference communi-
cation), author, year and country of study, number of donors, number
of donors with cancer, number of cancers discovered at procurement,
number of autopsies performed, number of cancers discovered at au-
topsy, whether donor underwent clinical and/or imaging investigations
andwhich ones, type and site of discovered cancer, which organs or tis-
sues were transplanted, outcome of recipients where present in terms
of transmission of malignancy.2.3. Quality assessment
The quality of studies was assessed independently by two authors
and disagreements were resolved by consultation of the third reviewer
according to a standardized checklist for quality assessment of case re-
ports and case series [17]. The specific items of the checklist weremod-
ified, given that not all the studies were likely to focus primarily on
autopsy, but they would likely be case reports of transmission events
or retrospective observational studies with descriptive information on
a population of donors.ngham NHS Foundation Trust from ClinicalKey.com by Elsevier on March 10, 2021.
 Copyright ©2021. Elsevier Inc. All rights reserved.
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A descriptive synthesis of absolute and relative frequencies of
discovered cancerswasprovidedwithnumerical values andpercentages.
Continuousmeasureswereexpressedasmedianandrange,whiledichot-
omous variableswere expressed as numerical values and percentages.
3. Results
3.1. Literature search
Of 7388 articles, after duplicates removal, 6863 were excluded after
the tile and abstract screening. The remaining 525were assessed in full-
text form and of these 56 were included. The flow of article screening
and inclusion is depicted in Fig. 1.
3.2. Quality appraisal
Over 70% of the studies clearly reported the post-mortem identifica-
tion of malignancy in the donor, the pathological diagnosis and the or-
gans transplanted and their outcome, whilst clear reporting of
demographic data of donors occurred in about 60% of studies. On the
contrary, only 27% of studies clearly reported whether imaging had
been undertaken in the donor and if so, which techniques were per-
formed, whilst this information was completely lacking in more thanFig. 1. Search flow of article scre
3
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3.3. Characteristics of studies
The included studies comprised 51 full articles, four abstracts and
one letter to the editor. The countries representedwere European coun-
tries in 34 (61%), United States in 18 (32%), Australia in 2 (4%) and Asian
countries in 2 (4%). Studieswere published in the timespan 1972–2019,
with 19 (34%) in the last decade. Half the studies (28, 50%)were case re-
ports of a single donor, 19 (33%) were retrospective studies with larger
series of donors ranging from 42 to 14,986 donors, seven studies (13%)
were small cases series with less than 20 donors, and in two cases (4%)
the exact number of the donors was not provided.
3.4. Frequency of donors, donors with cancer and autopsies
The number of donors ranged between 1 and 14,986 (median 1,
mean 871.2± 2623.3) with a total of 42,694 donors. The number of do-
nors with cancer ranged between 1 and 377 (median 1, mean 34.8 ±
81.6) with a total of 1704 donors with cancer. In most cases the cancers
were known about at time of transplantation, either from the donor his-
tory or investigations before the procurement. The number of autopsies
ranged between 1 and 246 (median 1,mean 17.9± 47.8)with a total of
823 autopsies performed. In 51 studies there was a whole-bodyening according to PRISMA.
ngham NHS Foundation Trust from ClinicalKey.com by Elsevier on March 10, 2021.
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tates and in 1 of the CNS.
3.5. Frequency of cancers discovered at procurement and at whole autopsy
The majority of unsuspected malignancies were identified at pro-
curement with a total of 277, with further 163 identified at autopsy.
The number discovered at procurement ranged between 0 and 124
(median 0, mean 6.3 ± 20.1) whilst the number discovered at autopsy
ranged between 1 and 29 (median 1, mean 3.2 ± 5.6). Of these per-
formed autopsies an unsuspected malignancy was identified in nearly
20%, however this is likely to be a too high as in some studies the
exact number of autopsies is not stated or only the number of autopsies
in which a cancer was identified was given. The histological type of
tumor was clearly provided in only 91 cases (56%), with no indication
as to the type of tumor in some.
The most frequent cancer discovered at autopsy was lymphoma
(n = 13, 15%), followed by renal cell carcinoma (RCC) (n = 11, 13%),
non-small cell lung cancer (NSCLC) (n = 10, 11%), melanoma (n =
10, 11%), choriocarcinoma (n = 6, 7%) and glioblastoma (GBM) (n =
6, 7%). A complete summary of cancers discovered with whole autopsy
with available data is found in Table 1.Table 1
Summary of cancers discovered with whole autopsy.




Lymphoma 13 6 M, 2 F, 5 NA
19–70 years














10 4 M, 2 F, 4 NA CRX and CT in 2
cases, NA for others
5 adenocarcinoma, 5 NOS
36–75 years
Melanoma 10 2 M, NA for
others Age NA
NA CNS mtx in 4 cases, spleen
mtx in 1 case
Choriocarcinoma 6 6 F NA CNS mtx in 3 cases
26–30 years
Glioblastoma 6 2 M, 4 NA CRX and CT in 1
case, NA for others
None of the GBM was
known before donation46–47 years




Prostate 5 53–71 years NA Mtx in 1 case, size
0.5–1.3 cm in 2 cases
Breast cancer 3 NA CRX, US and CT in 2
cases,
Size 0.3–0.5 cm in 2 cases,
1 ductal, 1 lobular 1 NA
1 NA
Other 22 7 M, 3 F, 12
NA 1–61 years
Total body CT in 1















1 liver cancer NOS
ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CNS, central nervous sy
phoma; F, female; GBM, glioblastoma; HCC, hepatocellular carcinoma;M,male;MRI, magnetic
NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; NSCLC, non-small cell lung cancer
carcinoma; SCC, squamous cell carcinoma; US, ultrasound examination.
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There were four studies [18–21] limited to autopsy assessment of
the prostate gland with a median number of donors of 148 (range
11–340), a median number of donors with prostate cancer of 12.5
(range 1–41) and a median number of cancers which were specifi-
cally discovered at the post-transplant/limited autopsy of 6.5
(range 1–41). In these studies, the prostate was studied after the re-
moval of organs or tissues and there were no transmission events in
the recipients. The PSA levels were reported in summary in three
studies [18–20], and there was not a statistically significant differ-
ence in cancer detection rates between donors with higher or nor-
mal PSA levels, and all conclude that PSA alone is not sufficient to
guide evaluation of the donor, but clinical exam and possibly pros-
tate organ examination is more useful.
One study [22] focused on the limited autopsy of the CNS
where definitive diagnosis was available after organ recovery. Of
8 donors, 7 had a primary CNS tumor of which 5 considered “be-
nign/low risk” by the authors and the transplant went ahead,
whilst in the case of the glioblastoma the transplant procedure
was canceled.
The studies with limited autopsy are summarized in Table 2.Organs transplanted Outcome
1 heart, 1 liver, tissue grafts,
15 kidneys, NA for others
Transmission in 10 cases, no transmission in 4
cases, NA for others
4 kidneys, 2 lungs, 1 heart,
tissue grafts, NA for others
Transmission in 4 cases, no transmission in 2, NA
for others
7 kidneys, 1 liver, 1 heart, 1
NA
Transmission in 6 cases, explanted kidneys in 2, NA
for others
7 kidney, 1 liver, 2 heart Transmission in 6 cases, explant in 1 case, no
transmission in 1 case, NA for others
4 kidneys, 2 liver, 2 heart, 2
lungs, 1 pancreas
Transmission in all cases
2 lung, 1 liver, 1 multiorgan, 2
NA
Transmission to the lung recipients
2 lung, 2 kidney, 1 cornea, 1
liver, 1 heart
3 explanted, no transmission in 1 case, NA for
others
1 heart, 2 liver 2 NA Transmission in the heart recipient
4 kidneys, 1 liver, 1 NA NA
5 tissue donors, 15 kidneys, 4
heart, 2 liver, NA for others
Transmission in 3 cases (PNET, mesothelioma, high
grade meningioma), 3 explants, NA for others
stem; CRX, chest radiography; CT, computed tomography; DLBCL, diffuse large B cell lym-
resonance imaging;MTC,medullary thyroid carcinoma;mtx, metastasis; NA, not available;
; PNET, primitive neuroectoderma tumor; PTC, papillary thyroid carcinoma; RCC, renal cell
ngham NHS Foundation Trust from ClinicalKey.com by Elsevier on March 10, 2021.
 Copyright ©2021. Elsevier Inc. All rights reserved.
Table 2
Summary of studies with limited autopsies.











Details of cancer Organs transplanted and outcome
Prostate
Frutos, 2003 (Spain) 11 Mean age 62.5 years, range
38–73 years




224 Mean age 60.9 years CRX, US,
PSA, DRE
13 6 NS 2 livers and 4 kidneys; no transmission
Skalski, 2018 (Poland) 72 Median age 63 years PSA, DRE NS 7 14 Gleason ≤6 7 livers; no transmission
5 Gleason >6
9 multifocal








8 7 F, 1 M; range 15–52 years MRI 8 7 1 GBM Transplant canceled for the GBM; no data






CNS, central nervous system; CRX, chest radiography; DRE, digital rectal examination; F, female; GBM, glioblastoma; M, male; MRI, magnetic resonance imaging; NS, not specified, PSA,
prostate specific antigen, US, ultrasound.
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The most frequent cancers discovered in donors at autopsy are lym-
phoma, renal cell carcinoma, non-small cell lung cancer andmelanoma,
followed by choriocarcinoma and glioblastoma. Lymphoma and mela-
nomaaredifficult-to-detect cancers as theydid not usually present as de-
tectablemasses or with clear-cut alterations in routine blood tests. There
is no unique strategy to increase the detection rate of thesemalignancies:
for example, a dermatologic examinationof thedonor canfindsuspicious
skin lesions, while a whole-body CT could highlight enlarged lymph
nodes to be searched for during surgical exploration and then sent to
the on-call pathologist for frozen section examination, however a frozen
section can only diagnose a high grade lymphoma and cannot exclude a
low grade lymphoma – this may lead to loss of organs if overzealous
use. The relatively higher number of renal cell carcinomas and lung can-
cer occurred before 2000when use of CT imagingwas not aswidespread
as at present day. Of note the “recent”missed lung cancerswere fromab-
dominal organ only donations where no thoracic exploration was made
at procurement [23,24]. This should not be surprising, as abdominal or-
gans are donated more often than thoracic ones. The “recent” missed
RCCwas from a tissue graft donor, from a large series where no informa-
tion on donor investigationwas provided [25,26]. The near complete ab-
sence of undetected choriocarcinoma in the last 25 years highlights the
important role of imaging and blood tests [27–29]. The recent case of un-
suspected choriocarcinoma occurred when betaHCG testing was not un-
dertaken in a pregnant female who died from a bleed from a presumed
vascular malformation [30]. Glioblastoma is another important cause of
death, with a significant risk of transmission to recipients that should
be suspected in young donors dying of cerebral hemorrhage events
[31–35]. Where neuroradiology is not available, then the risks of using a
cardiovascular accidents (CVA)donorwithno risk factors should be care-
fully considered, an autopsy limited to the brain could help to determine
the presence and the type of tumor and thendefine the level of risk, how-
ever this servicemay not bewidely available. GBM biomarkers are being
developed and may be helpful in donor screening in the future [36].
Rather surprisingly there is no documented detection of an unsuspected
gastrointestinal malignancy despite its high frequency in the general
population. Transmission of GI malignancy does occur but is rare consid-
ering the incidence in the general public, but the few that have been5
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successfully treated by retransplant [37].
Prostate adenocarcinoma is an incidental finding in autopsies, with
the increasing age of the donor pool there is an increasing chance of
an incidental prostate carcinoma being present. To try to detect these
in male donors a prostatic specific antigen (PSA) and digital rectal ex-
amination is performed, with slight protocol differences between coun-
tries [4,38,39]. The estimated incidence of prostate cancer identified in
donors, either diagnosed at procurement or after transplant, is between
3% and 18.5% [40] and risk of transmission relates to the Gleason grade
and staging. We found that in those detected at autopsy following
transplantation there was no cancer transmission, the only described
transmission was in a cardiac transplant recipient in whom the trans-
plantation procedure was nearly complete when enlarged pelvic
lymph nodes were discovered during abdominal organ retrieval, a fro-
zen section showed metastatic adenocarcinoma, subsequent autopsy
found advanced high grade and stage carcinoma of the prostate [41].
A major limitation of this study is the inability to be able to deter-
mine the incidence of an unsuspected malignancy being identified at
autopsy. The relatively high rate of first diagnosis of a donor malig-
nancy during autopsy after organ donation and transplantation
(163/823, 19.8%) identified in this review is almost certainly an
overestimate because the total number of autopsies is not reported
in many papers, just the number of autopsies in which malignancy
was identified. Further bias is likely due to reporting positive rather
than negative findings. Other issues that interfere with interpreta-
tion relate to the lack of complete information and methodology
being presented [42]. Other confounding factors include autopsies
done as part of research studies and for epidemiological purposes
and whether a review of registry data [25,29]. This review highlights
that a proportion of cancers still elude the donor investigations being
found and defined only at post-mortem. In this relatively small pro-
portion of recipients the discovery of a malignancy at autopsy allows
early and individualized management/treatment. It is however not
feasible to routinely perform an autopsy on all donors: there would
be significant costs in terms of personnel and biological material han-
dling, including the requirement of increased pathologists to be able to
undertake this number of postmortemswithout significant delay to rou-
tine diagnostic activity [7,8]. The potential loss of donors related to angham NHS Foundation Trust from ClinicalKey.com by Elsevier on March 10, 2021.
 Copyright ©2021. Elsevier Inc. All rights reserved.
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be taken into account. Whilst imaging techniques are not perfect [43],
they are increasingly replacing traditional autopsies [9,44]. Imaging tech-
niques are getting more sophisticated [11], and ability to digitally share
images for consultation has the potential tomaximize the pick-up of un-
suspected malignancies prior to transplantation. A recent retrospective
radiological series of 1644 donors found that screening of the donor
with whole-body CT did miss any lesions detected at the donor retrieval
operation,whereas chest x-rays and abdominal ultrasounddid. Aswould
be expectednot all suspicious lesionsdetectedbyCT turnedout to bema-
lignant and biopsy was required to assess. The identification of a suspi-
cious lesion ahead of surgery allows advance warning to pathologists to
organize their schedules rather than a “come now” phone call. The au-
thors concluded that the increased costs was outweighed by decreasing
the duration of the donation procedure and byminimizing the emotional
burden for the relatives of thedonor by identifyingpossible contraindica-
tions prior to procurement [43]. Further studies comparing imaging and
laboratory testing against the findings of an autopsy, the gold standard,
would help to answermany questions, but it is recognized that this is un-
likely to occur in any systematic manner, not least due to the wishes of
the family. Furthermore, considering the poor prognosis of a donor-
transmitted cancer [37,45], it would be reasonable to make any effort to
prevent this and detectmalignancies asmore as possible before procure-
ment. Similar considerations are also present in a study included [46],
where a structured procedure of donor evaluation which comprised
whole-body CT allowed the detection of 32 malignancies out of 400 do-
nors, with only 3 cancers missed and detected at post-mortem examina-
tionwhichwere however notmass-forming breast and liver cancer sized
less than 9 mm. However, autopsy still retains its value as it can lead to
the discovering of an unsuspected cancer, particularly for malignancies
difficult to detectwith routine available imaging techniques such as lym-
phoma and melanoma [42,47,48]. Reservation of autopsy procedure to
difficult and highly doubtful cases would balance the ethical duty to pre-
vent any harm to the recipient by discovering the cancer in a donor and
the need for control the costs and the correct allocation of human and
economic resources.
There have been improvementswith time in pre-donation detection
procedures which are now working well, particularly when complete
imaging investigations are performed, because, even with the ongoing
incomplete pick up on current advance imaging, the combined clinical,
serological, radiological and histopathological pathways detect the vast
majority of donors at risk of transmitting a malignancy. In summary, to
identify unsuspected donor malignancies with the potential for trans-
mission to the recipient an autopsy would need to be performed in spe-
cific donors' setting as is not a feasible option in all organ donors.
Autopsy indeed can represent another level of evidence to detect cancer
particularly in difficult cases and can help to better understand which
cancers are still eluding detection and consequently to refine the detec-
tion procedures, e.g. imaging procedures, new diagnostic markers or
targeted clinical investigations.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.trre.2021.100608.
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